Key facts
- This page summarizes Gregory D. Perry's Form 4 filing for Kala Pharmaceuticals, Inc. (KALA).
- 4 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 02 Jun 2023, 20:00.
Gregory D. Perry - 31 May 2023 Form 4 Insider Report for Kala Pharmaceuticals, Inc. (KALA)
- Reporting relationship
- Director
- Issuer ticker
- KALA
- Reported as of
- 31 May 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 02 Jun 2023, 20:00:46 UTC
- Prior SEC filing
- 17 Jun 2022
- Next SEC filing
- 12 Jun 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Mary Reumuth, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Gregory D. Perry filed Form 4 for Kala Pharmaceuticals, Inc. (KALA) on 02 Jun 2023.
Change
- Previous filing in this sequence was filed on 17 Jun 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
KALA
transaction
Common Stock
Award
- Transaction value
- Shares
- +1,738
- Change %
- +217%
- Price
- Shares after
- 2,538
- Date
- 31 May 2023
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
KALA
transaction
Derivative
Stock Option (right to buy)
Disposed to Issuer
- Transaction value
- Shares
- -518
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 31 May 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 518
- Exercise price
- $702.50
- Footnotes
- F1, F3, F4
KALA
transaction
Derivative
Stock Option (right to buy)
Disposed to Issuer
- Transaction value
- Shares
- -420
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 31 May 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 420
- Exercise price
- $267.50
- Footnotes
- F1, F3, F5
KALA
transaction
Derivative
Stock Option (right to buy)
Disposed to Issuer
- Transaction value
- Shares
- -800
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 31 May 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 800
- Exercise price
- $18.00
- Footnotes
- F1, F3, F6
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 6 footnotes
Footnote F1
On May 31, 2023, the issuer canceled, pursuant to the issuer's option exchange program, all outstanding unexercised options granted to the reporting person. In exchange, the reporting person received (i) in the case of the canceled options that were fully vested, a grant of 938 restricted stock units (the "RSUs") that vest over two years, with 50% of such RSUs vesting on May 31, 2024 and 50% of such RSUs vesting on May 31, 2025 and (ii) in the case of the canceled options that were unvested, a grant of 800 RSUs that vest 100% on May 31, 2025, in each case, subject to the reporting person's continued service with the issuer. Each RSU represents a contingent right to receive one share of the issuer's common stock.
Footnote F2
Includes 2,538 unvested or deferred RSUs.
Footnote F3
The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022.
Footnote F4
The cancelled option was granted on February 28, 2018 and provided for vesting with respect to 1/3rd of the shares on the first anniversary of the grant and with respect to an additional 1/36th of the shares on each monthly anniversary thereafter and was subject to vest automatically as to 100% of the unvested portion of such option upon specified change in control events.
Footnote F5
The cancelled option was granted on June 5, 2019 and provided for vesting with respect to 1/12th of the shares underlying the option at the end of each successive one-month period thereafter.
Footnote F6
The cancelled option was granted on June 16, 2022 and provided for vesting as to 100% of the shares underlying the option on the earlier of (i) June 16, 2023 or (ii) the date of the first annual meeting following June 16, 2022.